Ximelagatran Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Ximelagatran (XII), a prodrug of a direct thrombin inhibitor, melagatrin, was approved in the European Union in December, 2003, for the prevention of venous thromboembolic events in patients undergoing major elective orthopedic surgery, that is, hip or knee replacement. The FDA, however, did not approve the drug in the US based on the recommendation of the advisory panel.

Verwenden

Antithrombotic agent.

Ximelagatran Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Ximelagatran Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Suzhou yacoo science co.,Ltd	0512-87182056 18013166090	lingling.qi@yacoo.com.cn	China	7295	60
Suzhou yacoo science co.,Ltd	0512-87182056 13451648594	sales@yacoo.com.cn	China	4578	58

---

• Ximelagatran